

chain nodes :
 10 12 14 16 17 18 19 21 22 23
 ring nodes :
 1 2 3 4 5 6 7 8 9
 chain bonds :
 9-10 14-16 16-17 16-18 19-21 21-22 21-23
 ring bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
 exact/norm bonds :
 6-9 8-9 9-10 14-16 16-17 21-22 21-23
 exact bonds :
 5-7 7-8 16-18 19-21
 normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6
 isolated ring systems :
 containing 1 :



Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS 12:CLASS
 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS 21:CLASS
 22:CLASS 23:CLASS

Generic attributes :
 10:
 Saturation : Saturated

Element Count :
 Node 10: Limited
 C,C4-13

=>

Uploading C:\Program Files\Common Files\System\Mapi\1033\NT\10609224.str




chain nodes :
 10 12 14 16 17 18 19 21 22 23
 ring nodes :
 1 2 3 4 5 6 7 8 9
 chain bonds :
 9-10 14-16 16-17 16-18 19-21 21-22 21-23
 ring bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
 exact/norm bonds :
 6-9 8-9 9-10 14-16 16-17 21-22 21-23
 exact bonds :
 5-7 7-8 16-18 19-21
 normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6
 isolated ring systems :
 containing 1 :

Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS
 20:CLASS 21:CLASS 22:CLASS 23:CLASS
 Generic attributes :
 10:
 Saturation : Saturated

Element Count :
 Node 10: Limited
 C,C4-13

L1 STRUCTURE UPLOADED

=> d l1
 L1 HAS NO ANSWERS
 L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam
 SAMPLE SEARCH INITIATED 19:35:39 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 16290 TO ITERATE

6.1% PROCESSED 1000 ITERATIONS
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
 SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 318162 TO 333438
 PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 sss ful
 FULL SEARCH INITIATED 19:35:45 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 325249 TO ITERATE

100.0% PROCESSED 325249 ITERATIONS
 SEARCH TIME: 00.00.12

49 ANSWERS


L3 49 SEA SSS FUL L1

=> => s l3
 L4 9 L3

=> d l4 1-9 bib,ab,hitstr

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2004:80529 CAPLUS
 DN 140:133861
 TI ADP antagonists and ACAT inhibitors for treating arteriosclerosis
 IN Asai, Fumitoshi; Inaba, Toshimori; Ogawa, Taketoshi
 PA Sankyo Company, Limited, Japan
 SO PCT Int. Appl., 29 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004009119	A1	20040129	WO 2003-JP9108	20030717
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	JP 2004051639	A2	20040219	JP 2003-275276	20030716
PRAI	JP 2002-209165	A	20020718		
AB	A medicinal composition characterized in that an ADP receptor antagonist and an ACAT inhibitor, are administered either simultaneously or sep. at a definite interval. The medicinal composition is useful as a preventive or a remedy for arteriosclerosis or diseases derived from arteriosclerosis, such as ischemic heart disease, ischemic brain disease, and peripheral circulation failure in warm-blooded animals (in particular, humans). For example, pharmacol. activities of 2-acetoxy-5-(α -cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine (I) and N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide sulfuric acid salt (II) were studied using rabbits and tablets containing I 10 mg and II 30 mg each were formulated.				
IT	189198-30-9 189198-32-1 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (ADP antagonists and ACAT inhibitors for treatment of arteriosclerosis and related disorders thereof)				
RN	189198-30-9 CAPLUS				
CN	1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl- (9CI) (CA INDEX NAME)				




RN 189198-32-1 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl-, sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 189198-30-9


CMF C25 H40 N2 O3



CM 2

CRN 7664-93-9


CMF H2 O4 S



RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:818314 CAPLUS
 DN 139:297051
 TI Medicinal composition comprising ACAT inhibitor and insulin resistance improving agent
 IN Inaba, Toshimori; Fujiwara, Toshihiko
 PA Sankyo Company, Limited, Japan
 SO PCT Int. Appl., 29 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003084572	A1	20031016	WO 2003-JP4296	20030403
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	JP 2004002365	A2	20040108	JP 2003-101076	20030404
PRAI	JP 2002-103134	A	20020405		
AB	It is intended to provide a medicinal composition for preventing or treating arteriosclerosis or diseases caused by arteriosclerosis which comprises an ACAT inhibitor and an insulin resistance improving agent. For example, tablets were formulated containing 5-[[4-[(6-methoxy-1-methyl-1H-benzimidazol-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione hydrochloride 50, N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide hemisulfate 10, lactose 113, starch 25, and Mg stearate 2 mg/tablet.				
IT	189198-30-9 608510-47-0 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (medicinal composition comprising ACAT inhibitor and insulin resistance improving agent)				
RN	189198-30-9 CAPLUS				
CN	1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl- (9CI) (CA INDEX NAME)				




10/609,224

RN 608510-47-0 CAPLUS
CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-
4,6-dimethyl-1-octyl-, sulfate (2:1) (9CI) (CA INDEX NAME)


CM 1

CRN 189198-30-9
CMF C25 H40 N2 O3



CM 2


CRN 7664-93-9
CMF H2 O4 S



RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:202511 CAPLUS
 DN 138:226765
 TI Medicinal compositions containing angiotensin II receptor antagonists
 IN Sada, Toshio; Inaba, Toshimori
 PA Sankyo Company, Limited, Japan
 SO PCT Int. Appl., 26 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003020315	A1	20030313	WO 2002-JP8629	20020827
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	JP 2003146907	A2	20030521	JP 2002-246112	20020827
PRAI	JP 2001-257435	A	20010828		
AB	Disclosed are medicinal compns. for administering an angiotensin II receptor antagonist and an ACAT inhibitor either at the same time or sep. at a certain interval. The compns. are effective for the prevention and treatment of arteriosclerosis and cardiac ischemia. For example, tablets were formulated containing olmesartan 50, N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide 10, lactose 113, starch 25, and Mg stearate 2 mg/each.				
IT	189198-30-9 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (medicinal compns. containing angiotensin II receptor antagonist and ACAT inhibitor)				
RN	189198-30-9 CAPLUS				
CN	1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl- (9CI) (CA INDEX NAME)				



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:792270 CAPLUS
 DN 137:310809
 TI Preparation of indolines as intermediates for preparation of ACAT inhibitors
 IN Tanabe, Hideo; Oyama, Yuzuru; Kiyota, Hiroshi
 PA Sankyo Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 10 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2002302481	A2	20021018	JP 2002-24876	20020201
PRAI	JP 2001-26375	A	20010202		
OS	MARPAT 137:310809				

AB The compds. I (R1, R2 = lower alkyl; R3 = octyl) or their salts are prepared by deprotection of I (R1, R2 = lower alkyl; R3 = amino-protecting group) or their salts and octylation of I (R1, R2 = lower alkyl; R3 = H) or their salts. Carboxyindolines II (R1, R2 = lower alkyl) are prepared from I (R1, R2 = lower alkyl; R3 = octyl). N-(1-acetyl-5-cyanomethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide was reacted with NaOMe in MeOH under reflux for 6 h, alkylated with octyl bromide in the presence of (iso-Pr)₂NEt in xylene under reflux for 12 h, hydrolyzed in the presence of aqueous NaOH in PrOH under reflux for 15 h, and treated with H₂SO₄ in acetone-H₂O mixture to give 83% N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide sulfate.

IT **189198-32-1P**

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of indolines as intermediates for preparation of ACAT inhibitors)


RN 189198-32-1 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl-, sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 189198-30-9


CMF C25 H40 N2 O3



CM 2


10/609,224

CRN 7664-93-9
CMF H2 O4 S



L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:716126 CAPLUS
 DN 137:252985
 TI Medicinal compositions containing bile acid transporter inhibitor and
 cholesterol acyltransferase inhibitors
 IN Inaba, Toshimori
 PA Sankyo Company, Limited, Japan
 SO PCT Int. Appl., 70 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002072147	A1	20020919	WO 2002-JP2311	20020312
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	JP 2002338496	A2	20021127	JP 2002-67841	20020313
PRAI	JP 2001-72050	A	20010314		
AB	Disclosed are medicinal compns. for administering an ileal bile acid transporter inhibitor and a cholesterol acyltransferase (ACAT) inhibitor either at the same time or sep. at a certain interval. The effect of oral administration of both 4-[3-[(1-(3,5-difluorophenyl)ethylamino)-(4- methoxyphenyl)methyl]phenylamino]-3-hydroxy-3-cyclobutene-1,2-dione (I) and N-(1-octyl-5-carboxymethyl-4,6-dimethylindoline-7-yl)-2,2- dimethylpropaneamide (II) on blood serum triglyceride was prepared Also, a tablet containing I 50, II 30, lactose 368, corn starch 50, magnesium stearate 2 mg was prepared				
IT	189198-30-9 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (hypolipemic compns. containing bile acid transporter inhibitor and cholesterol acyltransferase inhibitors)				
RN	189198-30-9 CAPLUS				
CN	1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro- 4,6-dimethyl-1-octyl- (9CI) (CA INDEX NAME)				



L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:615568 CAPLUS

DN 137:169415

TI Preparation of indoline derivatives as acyl-coenzyme A:cholesterol acyltransferase inhibitors

IN Tomori, Hiroshi; Miyamoto, Hiroshi; Fukuhara, Hiroshi; Sonobe, Ryuichi; Miura, Motoko; Shimura, Kazuhiko; Fujimoto, Katsuhiko; Wakayama, Masakazu

PA Sankyo Company, Limited, Japan

SO PCT Int. Appl., 67 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002062758	A1	20020815	WO 2002-JP804	20020201
	W: AU, BR, CA, CN, CO, CZ, HU, ID, IL, IN, KR, MX, NO, NZ, PH, PL, RU, SG, SK, US, VN, ZA				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
	JP 2002302482	A2	20021018	JP 2002-24877	20020201
	EP 1364942	A1	20031126	EP 2002-710441	20020201
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
	US 2004058979	A1	20040325	US 2003-635040	20030731
	NO 2003003432	A	20031001	NO 2003-3432	20030801
PRAI	JP 2001-26374	A	20010202		
	WO 2002-JP804	W	20020201		
OS	CASREACT 137:169415; MARPAT 137:169415				
AB	Novel intermediates such as I and II useful for synthesizing an indoline derivative having excellent acyl-CoA:cholesterol acyltransferase (ACAT) inhibitory activity are prepared (R1 = an amino-protecting group; R2 and R3 = lower alkyl; and R4 = H or a carboxy-protecting group). Reaction of 1-acetyl-4,6-dimethylindoline with glyoxylic acid, hydrogenolysis with Pd-C and esterification with saturated HCl-EtOH solution, followed by nitration, hydrogenation, reaction with pivaloyl chloride, deacetylation, reaction with octyl bromide and base hydrolysis gave N-(5-carboxymethyl-4,6-dimethyl-1-octylindolin-7-yl)-2,2-dimethylpropanamide sulfuric acid salt.				
IT	189198-32-1P				
	RL: SPN (Synthetic preparation); PREP (Preparation) (indoline derivative useful for ACAT inhibitor and their preparation)				
RN	189198-32-1 CAPLUS				
CN	1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl-, sulfate (1:1) (9CI) (CA INDEX NAME)				

CM 1

CRN 189198-30-9

CMF C25 H40 N2 O3


10/609,224



CM 2

CRN 7664-93-9

CMF H2 O4 S




RE.CNT 8

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:184896 CAPLUS
 DN 136:236854
 TI Medicinal compositions for administration of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide and HMG-CoA reductase inhibitors
 IN Kohama, Takafumi; Inaba, Toshimori
 PA Sankyo Company, Ltd., Japan
 SO PCT Int. Appl., 26 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002020009	A1	20020314	WO 2001-JP7438	20010829
	W: AU, BR, CA, CN, CO, CZ, HU, ID, IL, IN, KR, MX, NO, NZ, PL, RU, SG, SK, US, ZA				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
	AU 2001082541	A5	20020322	AU 2001-82541	20010829
	EP 1314423	A1	20030528	EP 2001-961177	20010829
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
	US 2002055533	A1	20020509	US 2001-943712	20010831
	JP 2002145774	A2	20020522	JP 2001-262600	20010831
	NO 2003000946	A	20030408	NO 2003-946	20030228
PRAI	JP 2000-265082	A	20000901		
	US 2000-230601P	P	20000906		
	WO 2001-JP7438	W	20010829		
AB	Disclosed are medicinal compns. for administering N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide or its pharmacol. acceptable salt and an HMG-CoA reductase inhibitor either at the same time or sep. after a definite period of time. Blood lipid-lowering effect of oral administration of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide sulfate (I) 30 and pravastatin 3 mg/kg in hamsters was examined Also, tablet containing I 30, sodium pravastatin 10, lactose 408, corn starch 50, and magnesium stearate 2 mg was formulated.				
IT	189198-32-1 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (medicinal compns. for administration of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide and HMG-CoA reductase inhibitors)				
RN	189198-32-1 CAPLUS				
CN	1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl-, sulfate (1:1) (9CI) (CA INDEX NAME)				
CM	1				
CRN	189198-30-9				
CMF	C25 H40 N2 O3				



CM 2

CRN 7664-93-9

CMF H2 O4 S




IT 189198-30-9

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (medicinal compns. for administration of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide and HMG-CoA reductase inhibitors)

RN 189198-30-9 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl- (9CI) (CA INDEX NAME)




RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:113163 CAPLUS
 DN 136:167280
 TI Preparation of 5-carboxymethylindolines
 IN Kamiya, Shoji; Matsui, Hiroshi
 PA Kyoto Pharmaceutical Industries, Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 11 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2002047269	A2	20020212	JP 2000-233250	20000801
PRAI	JP 2000-233250		20000801		
OS	CASREACT 136:167280; MARPAT 136:167280				
AB	<p>The compds. I (Y = CO₂H; R₁ = alkyl, alkenyl, alkoxyalkyl, alkylthioalkyl, etc.; R₂, R₃, R₅ = H, lower alkyl, lower alkoxy; R₄ = alkyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, etc.; A = alkylene; Z = CH₂CH₂, CH:CH) or their salts, as ACAT and lipid peroxidn. inhibitors, are prepared by carbamoylation of cyano compds. I (Y = cyano; R₁ = protecting group; R₂, R₃, R₅, A, Z = same as above), reaction of I (Y = CONH₂; R₁ = H; R₂, R₃, R₅, A, Z = same as above) or their salts with R₁X (R₁ = same as above; X = leaving group), and carboxylation of I (Y = CONH₂; R₁ = alkyl, alkenyl, alkoxyalkyl, alkylthioalkyl, etc.; R₂, R₃, R₅, A, Z = same as above) or their salts. N-(1-acetyl-5-cyanomethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide was treated with NaOH in MeOH under reflux for 20 h and alkylated with n-octyl bromide in DMF in the presence of K₂CO₃ and KI at 40° for 24 h to give N-(5-carbamoylmethyl-4,6-dimethyl-1-octylindolin-7-yl)-2,2-dimethylpropanamide, which was treated with NaOH in ProH at 90-100° for 12 h to give 98% N-(5-carboxymethyl-4,6-dimethyl-1-octylindolin-7-yl)-2,2-dimethylpropanamide sulfate .</p>				
IT	<p>189198-32-1P RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation) (preparation of carboxymethylindolines)</p>				
RN	189198-32-1 CAPLUS				
CN	1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl-, sulfate (1:1) (9CI) (CA INDEX NAME)				

CM 1

CRN 189198-30-9
 CMF C25 H40 N2 O3




10/609,224

CM 2

CRN 7664-93-9

CMF H2 O4 S



L4 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1997:326877 CAPLUS

DN 126:305540

TI Preparation of benzene-fused heterocyclic derivatives as inhibitors of acyl-coenzyme A:cholesterol acyltransferase (ACAT) and medicinal use thereof

IN Kamiya, Shoji; Shirahase, Hiroaki; Matsui, Hiroshi; Nakamura, Shohei; Wada, Katsuo

PA Kyoto Pharmaceutical Industries, Ltd., Japan

SO PCT Int. Appl., 121 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9712860	A1	19970410	WO 1996-JP2852	19960930
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI				
	CA 2233842	AA	19970410	CA 1996-2233842	19960930
	AU 9670977	A1	19970428	AU 1996-70977	19960930
	AU 708571	B2	19990805		
	EP 866059	A1	19980923	EP 1996-932060	19960930
	EP 866059	B1	20011205		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	CN 1203587	A	19981230	CN 1996-198670	19960930
	CN 1097043	B	20021225		
	BR 9610846	A	19990713	BR 1996-10846	19960930
	JP 2968050	B2	19991025	JP 1996-514152	19960930
	RU 2173316	C2	20010910	RU 1998-108605	19960930
	IL 123939	A1	20011125	IL 1996-123939	19960930
	AT 210116	E	20011215	AT 1996-932060	19960930
	ES 2164920	T3	20020301	ES 1996-932060	19960930
	PT 866059	T	20020328	PT 1996-96932060	19960930
	CZ 292632	B6	20031112	CZ 1998-996	19960930
	TW 429250	B	20010411	TW 1996-85112125	19961004
	NO 9801485	A	19980602	NO 1998-1485	19980401
	US 6063806	A	20000516	US 1998-51202	19980403
	HK 1015781	A1	20030822	HK 1999-100913	19990305
	US 6200988	B1	20010313	US 2000-506839	20000218
	CN 1361100	A	20020731	CN 2001-142957	20011130
PRAI	JP 1995-259082	A	19951005		
	JP 1996-58018	A	19960314		
	JP 1996-194331	A	19960724		
	WO 1996-JP2852	W	19960930		
OS	MARPAT 126:305540				
AB	Heterocyclic derivs. represented by general formula (I; one of R1, R2, and R5 = OH, CO2H, alkoxycarbonyl, NR9R10, or alkyl or alkenyl substituted by OH, acidic group, or NR9R10 and the others = H, lower alkyl or alkoxy; wherein R9, R10 = H, lower alkyl; one of R3 and R4 = NHCOR7 and the other = H, lower alkyl or alkoxy; wherein R7 = alkyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, NHR8;				

wherein R8 = alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl; R6 = alkyl, alkenyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, cycloalkylalkyl, arylalkyl; Z = a linkage group required to form a 5- to 6-membered ring together with NR6 and C atoms of the benzene ring) or pharmaceutically acceptable salts thereof are prepared. The compds. or pharmaceutically acceptable salts thereof show excellent effects of inhibiting ACAT and inhibiting the peroxidn. of lipids on mammals and thus are useful as ACAT inhibitors and lipid peroxidn. inhibitors. Namely, they are useful in the prevention and treatment of, for example, arteriosclerosis, hyperlipemia, arteriosclerotic lesions in association with diabetes, and ischemic diseases in brain and heart. Thus, N-(1-acetyl-5-chloromethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide was heated with AcOK in MeCN/DMF at 60° under stirring for 1 h, followed by saponification with NaOH in aqueous EtOH under reflux, to give N-(5-hydroxymethyl-4,6-dimethylindolyl-7-yl)-2,2-dimethylpropanamide, which was alkylated by 1-iodooctane in the presence of K₂CO₃ in DMF to give at 50° for 2 h N-(1-octyl-5-hydroxymethyl-4,6-dimethylindolyl-7-yl)-2,2-dimethylpropanamide (II). II in vitro inhibited by 99.2% the production of cholesteryl oleate from [1-¹⁴C]oleoyl CoA in microsome fraction of rabbit small intestinal membrane and at 10 mg/kg per day for 3 days in vivo lowered by 57.1% a total serum cholesterol in rats fed with a high cholesterol diet.


IT 189198-29-6P 189198-30-9P 189198-31-0P
 189198-32-1P 189198-33-2P 189198-34-3P
 189198-38-7P 189198-40-1P 189198-43-4P
 189198-46-7P 189198-47-8P 189198-49-0P
 189198-51-4P 189198-52-5P 189198-55-8P
 189198-56-9P 189198-58-1P 189198-59-2P
 189198-60-5P 189198-61-6P 189198-62-7P
 189198-63-8P 189198-64-9P 189198-65-0P
 189198-66-1P 189198-67-2P 189198-68-3P
 189198-69-4P 189198-70-7P 189198-71-8P
 189198-72-9P 189198-73-0P 189198-74-1P
 189198-75-2P 189198-94-5P 189198-95-6P
 189198-96-7P 189198-97-8P 189198-98-9P
 189199-33-5P 189199-34-6P 189199-36-8P
 189199-38-0P 189199-41-5P 189199-42-6P
 189199-43-7P 189199-44-8P 189199-46-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzene-fused heterocyclic derivs. as inhibitor of acyl-CoA:cholesterol acyltransferase and lipid peroxidn. for disease therapy)


RN 189198-29-6 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 189198-30-9 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl- (9CI) (CA INDEX NAME)



RN 189198-31-0 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 189198-32-1 CAPLUS


CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl-, sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 189198-30-9

10/609,224


CMF C25 H40 N2 O3



CM 2

CRN 7664-93-9

CMF H2 O4 S




RN 189198-33-2 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl-, mononitrate (9CI) (CA INDEX NAME)

CM 1

CRN 189198-30-9


CMF C25 H40 N2 O3



CM 2


CRN 7697-37-2

CMF H N O3




RN 189198-34-3 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl-, monosodium salt (9CI) (CA INDEX NAME)




RN 189198-38-7 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-pentyl- (9CI) (CA INDEX NAME)




RN 189198-40-1 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-(3-methylbutyl)- (9CI) (CA INDEX NAME)




RN 189198-43-4 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-1-hexyl-2,3-dihydro-4,6-dimethyl- (9CI) (CA INDEX NAME)




RN 189198-46-7 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-(4-methylpentyl)- (9CI) (CA INDEX NAME)




RN 189198-47-8 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-1-(2-ethylbutyl)-2,3-dihydro-4,6-dimethyl- (9CI) (CA INDEX NAME)




RN 189198-49-0 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-1-heptyl-2,3-dihydro-4,6-dimethyl- (9CI) (CA INDEX NAME)




RN 189198-51-4 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-(5-methylhexyl)- (9CI) (CA INDEX NAME)




RN 189198-52-5 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-1-(3-ethylpentyl)-2,3-dihydro-4,6-dimethyl- (9CI) (CA INDEX NAME)




RN 189198-55-8 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-(6-methylheptyl)- (9CI) (CA INDEX NAME)




RN 189198-56-9 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-1-(4-ethylhexyl)-2,3-dihydro-4,6-dimethyl- (9CI) (CA INDEX NAME)




RN 189198-58-1 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-nonyl- (9CI) (CA INDEX NAME)




RN 189198-59-2 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-(7-methyloctyl)- (9CI) (CA INDEX NAME)




RN 189198-60-5 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-1-(5-ethylheptyl)-2,3-dihydro-4,6-dimethyl- (9CI) (CA INDEX NAME)




RN 189198-61-6 CAPLUS

CN 1H-Indole-5-acetic acid, 1-decyl-7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl- (9CI) (CA INDEX NAME)




RN 189198-62-7 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-(8-methylnonyl)- (9CI) (CA INDEX NAME)




RN 189198-63-8 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-undecyl- (9CI) (CA INDEX NAME)




RN 189198-64-9 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-(9-methyldecyl)- (9CI) (CA INDEX NAME)




RN 189198-65-0 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-1-dodecyl-2,3-dihydro-4,6-dimethyl- (9CI) (CA INDEX NAME)




RN 189198-66-1 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-(10-methylundecyl)- (9CI) (CA INDEX NAME)




RN 189198-67-2 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxohexyl)amino]-1-hexyl-2,3-dihydro-4,6-dimethyl- (9CI) (CA INDEX NAME)




RN 189198-68-3 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxohexyl)amino]-1-heptyl-2,3-dihydro-4,6-dimethyl- (9CI) (CA INDEX NAME)




RN 189198-69-4 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxohexyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl- (9CI) (CA INDEX NAME)




RN 189198-70-7 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxooctyl)amino]-1-hexyl-2,3-dihydro-4,6-dimethyl- (9CI) (CA INDEX NAME)




RN 189198-71-8 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxooctyl)amino]-1-heptyl-2,3-dihydro-4,6-dimethyl- (9CI) (CA INDEX NAME)




RN 189198-72-9 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxooctyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl- (9CI) (CA INDEX NAME)




RN 189198-73-0 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxodecyl)amino]-1-hexyl-2,3-dihydro-4,6-dimethyl- (9CI) (CA INDEX NAME)




RN 189198-74-1 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxodecyl)amino]-1-heptyl-2,3-dihydro-4,6-dimethyl- (9CI) (CA INDEX NAME)




RN 189198-75-2 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxodecyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl- (9CI) (CA INDEX NAME)




RN 189198-94-5 CAPLUS

CN 1H-Indole-5-acetic acid, 1-hexyl-2,3-dihydro-6-methyl-7-[(1-oxopentyl)amino]- (9CI) (CA INDEX NAME)




RN 189198-95-6 CAPLUS

CN 1H-Indole-5-acetic acid, 1-heptyl-2,3-dihydro-6-methyl-7-[(1-oxopentyl)amino]- (9CI) (CA INDEX NAME)




RN 189198-96-7 CAPLUS

CN 1H-Indole-5-acetic acid, 2,3-dihydro-6-methyl-1-octyl-7-[(1-oxopentyl)amino]- (9CI) (CA INDEX NAME)




RN 189198-97-8 CAPLUS

CN 1H-Indole-5-acetic acid, 2,3-dihydro-6-methyl-1-nonyl-7-[(1-oxopentyl)amino]- (9CI) (CA INDEX NAME)




RN 189198-98-9 CAPLUS

CN 1H-Indole-5-acetic acid, 1-decyl-2,3-dihydro-6-methyl-7-[(1-oxopentyl)amino]- (9CI) (CA INDEX NAME)




RN 189199-33-5 CAPLUS

CN 1H-Indole-5-acetic acid, 2,3-dihydro-7-[(3-methoxy-1-oxopropyl)amino]-4,6-dimethyl-1-octyl- (9CI) (CA INDEX NAME)




RN 189199-34-6 CAPLUS

CN 1H-Indole-5-acetic acid, 2,3-dihydro-4,6-dimethyl-7-[[3-(methylthio)-1-oxopropyl]amino]-1-octyl- (9CI) (CA INDEX NAME)




RN 189199-36-8 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(cyclohexylacetyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl- (9CI) (CA INDEX NAME)




RN 189199-38-0 CAPLUS

CN 1H-Indole-5-acetic acid, 2,3-dihydro-4,6-dimethyl-1-octyl-7-[(phenylacetyl)amino]- (9CI) (CA INDEX NAME)




RN 189199-41-5 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-6-methyl-1-octyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 189199-42-6 CAPLUS

CN 1H-Indole-4-acetic acid, 6-[(2,2-dimethyl-1-oxopropyl)amino]-1-hexyl-2,3-dihydro-5,7-dimethyl- (9CI) (CA INDEX NAME)




RN 189199-43-7 CAPLUS

CN 1H-Indole-4-acetic acid, 6-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-5,7-dimethyl-1-nonyl- (9CI) (CA INDEX NAME)




RN 189199-44-8 CAPLUS

CN 1H-Indole-4-acetic acid, 6-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-5,7-dimethyl-1-undecyl- (9CI) (CA INDEX NAME)



RN 189199-46-0 CAPLUS

CN 1H-Indole-5-acetic acid, 1-[6-(butylthio)hexyl]-7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl- (9CI) (CA INDEX NAME)



10/609,224

=> => d his

(FILE 'HOME' ENTERED AT 19:35:01 ON 27 APR 2004)

FILE 'REGISTRY' ENTERED AT 19:35:15 ON 27 APR 2004

L1 STRUCTURE UPLOADED
L2 0 S L1 SSS SAM
L3 49 S L1 SSS FUL

FILE 'CAPLUS' ENTERED AT 19:36:04 ON 27 APR 2004

L4 9 S L3

FILE 'CAOLD' ENTERED AT 19:36:32 ON 27 APR 2004

=> s l3

L5 0 L3

=> log y

COST IN U.S. DOLLARS

SINCE FILE
ENTRY

TOTAL
SESSION

FULL ESTIMATED COST

0.42

199.30

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE
ENTRY

TOTAL
SESSION

CA SUBSCRIBER PRICE

0.00

-6.24

STN INTERNATIONAL LOGOFF AT 19:36:44 ON 27 APR 2004